Welcome to the international HTA database

Showing [16861 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2021	Austrian Institute for Health Technology Assessment (AIHTA)	Robotics and functional electrical stimulation for stroke rehabilitation: systematic review
2021	Austrian Institute for Health Technology Assessment (AIHTA)	[Parent-Child-Pass Update 2020/21 – Screenings for mental health, nutrition and social competence]
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Ambulatory blood glucose checks
2021	Agency for Care Effectiveness (ACE)	Tenofovir alafenamide for treating chronic hepatitis B infection
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Prevention of opioid-induced respiratory depression (OIRD) in hospital care
2021	Agency for Care Effectiveness (ACE)	Metformin extended release for treating type 2 diabetes mellitus
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Ventral rectopexy for the treatment of rectal prolapse and intussusception
2021	NIHR Health Technology Assessment programme	Social recovery therapy for young people with emerging severe mental illness: the Prodigy RCT
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Fall prevention in ambulatory care facilities
2021	Agency for Care Effectiveness (ACE)	Guselkumab, ixekizumab and secukinumab for treating chronic plaque psoriasis
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Endoscopic sleeve gastroplasty for the treatment of patients with Class I and II obesity who have failed first-line (lifestyle modification) and second-line (VLED/pharmacotherapy) treatments
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Triaging COVID-19 in the emergency department
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Belantamab mafodotin (multiple myeloma, at least 4 prior therapies, monotherapy)]
2021	Agency for Care Effectiveness (ACE)	Ixekizumab and secukinumab for treating active psoriatic arthritis
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Permanent acute coronary syndrome event detector (insertion, removal or replacement of) for monitoring of the heart's electrical activity
2021	National Institute for Health and Care Excellence (NICE)	SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea. NICE diagnostics guidance 44
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Critical value thresholds
2021	Agency for Care Effectiveness (ACE)	Dacomitinib for treating EGFR mutation-positive non-small-cell lung cancer
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Modification of the wording of minimally invasive glaucoma surgery (MIGS) existing item number to encompass the use of a microcatheter
2021	National Institute for Health and Care Excellence (NICE)	QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography. NICE diagnostics guidance 43
2021	Health Technology Wales (HTW)	Corneal crosslinking to treat adults and children with keratoconus
2021	Agency for Care Effectiveness (ACE)	Ixekizumab and secukinumab for treating active ankylosing spondylitis
2021	Agency for Healthcare Research and Quality (AHRQ)	Treatments and technologies supporting appropriate opioid tapers
2021	Health Technology Wales (HTW)	Freestyle Libre flash glucose monitoring for the management of diabetes
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Bulevirtide (chronic hepatitis delta virus (HDV) infection)]
2021	Agency for Healthcare Research and Quality (AHRQ)	Treatments, technologies, and models for management of acute and chronic pain in people with a history of substance use disorder
2021	NIHR Health Technology Assessment programme	Estimating the benefits and harms of Z-drugs for people with dementia and sleep disorders
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Afamelanotide (Reassessment after the deadline: Phototoxicity in erythropoietic protoporphyria (EPP))]
2021	NIHR Health Technology Assessment programme	Preventing enduring behavioural problems in young children through early psychological intervention: Healthy Start, Happy Start
2021	Norwegian Institute of Public Health (NIPH)	Minimally invasive glaucoma surgery (MIGS) for individuals with glaucoma. A health technology assessment
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Crizanlizumab (repeal of the resolution of 20 May 2021)]
2021	NIHR Health Technology Assessment programme	Statin Web-based Investigation of Side Effects Trial (Statin WISE Trial)
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Fedratinib (myelofibrosis)]
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Modification of the wording of minimally invasive glaucoma surgery (MIGS) existing item number to encompass the use of a microcatheter
2021	NIHR Health Technology Assessment programme	Prognostic indicators of severe disease in late preterm pre-eclampsia to guide decision making on timing of delivery: the PEACOCK study
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Fenfluramine (Dravet syndrome, ≥ 2 years)]
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Alpha-1 antitrypsin genotyping
2021	NIHR Health Technology Assessment programme	A randomized controlled trial to study the effectiveness of laser ablation versus observation to prevent anal cancer in men with human immunodeficiency virus who have high-grade anal intraepithelial neoplasia
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Streamlining Medicare Benefits Schedule items for positron emission tomography (PET) project
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Glasdegib (acute myeloid leukaemia (AML), combination with cytarabine (LDAC))]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Imlifidase (desensitisation in kidney transplantation)]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ivacaftor/Tezacaftor/Elexacaftor (Exceeding the € 50 Million Limit, Cystic Fibrosis, Combination Treatment with Ivacaftor in Patients 12 Years and Older (Heterozygous for F508del and MF Mutation))]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ivacaftor/Tezacaftor/Elexacaftor (exceeding the € 50 million limit, cystic fibrosis, combination treatment with Ivacaftor in patients 12 years and older (homozygous for F508del mutation))]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Lumasiran (Hyperoxaluria)]
2021	NIHR Health Services and Delivery Research programme	Progressive exercise compared with best-practice advice, with or without corticosteroid injection, for rotator cuff disorders: the GRASP factorial RCT
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Luspatercept (Myelodysplastic Syndrome (MDS))]
2021	Malaysian Health Technology Assessment (MaHTAS)	Hyperthermic intraperitoneal chemotherapy as an adjuvant therapy for peritoneal surface malignancy (PSM)
2021	NIHR Public Health Research (PHR) programme	Does slip resistant footwear reduce slips among healthcare workers? A randomised controlled trial
2021	National Institute for Health and Care Excellence (NICE)	Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer. NICE technology appraisal guidance 668
2021	NIHR Health Technology Assessment programme	Tranexamic acid to reduce head injury death in people with traumatic brain injury: the CRASH-3 international RCT
2021	NIHR Health Technology Assessment programme	Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Artificial intelligence in surgery and surgical education
2021	National Institute for Health and Care Excellence (NICE)	Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor. NICE technology appraisal guidance 670
2021	Swiss Federal Office of Public Health (FOPH)	Long-term physiotherapy in patients after stroke, with multiple sclerosis, or with Parkinson’s disease
2021	National Institute for Health and Care Excellence (NICE)	Mepolizumab for treating severe eosinophilic asthma. NICE technology appraisal guidance 671
2021	NIHR Public Health Research (PHR) programme	An online family-based self-monitoring and goal-setting intervention to improve children’s physical activity: the FRESH feasibility trial and three-arm pilot RCT
2021	National Institute for Health and Care Excellence (NICE)	Brolucizumab for treating wet age-related macular degeneration. NICE technology appraisal guidance 672
2021	National Institute for Health and Care Excellence (NICE)	Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. NICE technology appraisal guidance 673
2021	National Institute for Health and Care Excellence (NICE)	Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal). NICE technology appraisal guidance 674
2021	National Institute for Health and Care Excellence (NICE)	Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal). NICE technology appraisal guidance 675
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Luspatercept (β-thalassaemia)]
2021	National Institute for Health and Care Excellence (NICE)	Filgotinib for treating moderate to severe rheumatoid arthritis. NICE technology appraisal guidance 676
2021	National Institute for Health and Care Excellence (NICE)	Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma. NICE technology appraisal guidance 677
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Effectiveness and safety of vitamin B12 tests
2021	National Institute for Health and Care Excellence (NICE)	Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal). NICE technology appraisal guidance 678
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Osilodrostat (Endogenous Cushing’s Syndrome)]
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Long-term physiotherapy in patients after stroke, with multiple sclerosis, or with Parkinson's disease
2021	National Institute for Health and Care Excellence (NICE)	Dapagliflozin for treating chronic heart failure with reduced ejection fraction. NICE technology appraisal guidance 679
2021	National Institute for Health and Care Excellence (NICE)	Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma. NICE technology appraisal guidance 680
2021	Austrian Institute for Health Technology Assessment (AIHTA)	Implantation of bulking agents for faecal incontinence. Update 2021: systematic review
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Pemigatinib (cholangiocarcinoma with FGFR2 fusion or FGFR2 rearrangement, after at least one prior therapy)]
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Ezetimibe-containing medicines for the treatment of hypercholesterolaemia and mixed/combined hyperlipidaemia
2021	National Institute for Health and Care Excellence (NICE)	Baricitinib for treating moderate to severe atopic dermatitis. NICE technology appraisal guidance 681
2021	Austrian Institute for Health Technology Assessment (AIHTA)	Percutaneous left ventricular assist devices: micro-axial flow pumps: systematic review
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Denosumab (Prolia) for the treatment of osteoporosis
2021	National Institute for Health and Care Excellence (NICE)	Erenumab for preventing migraine. NICE technology appraisal guidance 682
2021	Austrian Institute for Health Technology Assessment (AIHTA)	Liposuction for surgical therapy of lipoedema: systematic review
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Subacromial decompression as a primary/isolated intervention to treat subacromial pain
2021	National Institute for Health and Care Excellence (NICE)	Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer. NICE technology appraisal guidance 683
2021	Austrian Institute for Health Technology Assessment (AIHTA)	Triphasic biomaterial for augmentation of the osteoporotic femoral neck: systematic review
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Corneal collagen crosslinking for the treatment of progressive keratoconus
2021	National Institute for Health and Care Excellence (NICE)	Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease. NICE technology appraisal guidance 684
2021	NIHR Health Technology Assessment programme	Adrenaline to improve survival in out-of-hospital cardiac arrest: the PARAMEDIC2 RCT
2021	Austrian Institute for Health Technology Assessment (AIHTA)	Endoscopic plication therapy in patients with gastroesophageal reflux disease (GERD): systematic review
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Sebelipase alfa (reassessment after expiry of the deadline (lysosomal acid lipase deficiency))]
2021	National Institute for Health and Care Excellence (NICE)	Anakinra for treating Still's disease. NICE technology appraisal guidance 685
2021	Austrian Institute for Health Technology Assessment (AIHTA)	Allogenic bone screw Shark Screw® in patients with hallux valgus or scaphoid fractures/pseudarthroses: systematic review
2021	National Institute for Health and Care Excellence (NICE)	Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal). NICE technology appraisal guidance 686
2021	National Institute for Health and Care Excellence (NICE)	Transanal total mesorectal excision for rectal cancer. NICE interventional procedures guidance 713
2021	Austrian Institute for Health Technology Assessment (AIHTA)	(Good) practice organisational models using real-world evidence for public funding of high priced therapies
2021	National Institute for Health and Care Excellence (NICE)	Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. NICE technology appraisal guidance 687
2021	National Institute for Health and Care Excellence (NICE)	Endobronchial nerve ablation for chronic obstructive pulmonary disease. NICE interventional procedures guidance 714
2021	National Institute for Health and Care Excellence (NICE)	Selective internal radiation therapies for treating hepatocellular carcinoma. NICE technology appraisal guidance 688
2021	National Institute for Health and Care Excellence (NICE)	Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure. NICE interventional procedures guidance 711
2021	National Institute for Health and Care Excellence (NICE)	Acalabrutinib for treating chronic lymphocytic leukaemia. NICE technology appraisal guidance 689
2021	National Institute for Health and Care Excellence (NICE)	Coronary sinus narrowing device implantation for refractory angina. NICE interventional procedures guidance 712
2021	Scottish Health Technologies Group (SHTG)	Elective surgery using mesh to repair primary or incisional hernias in adults
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Tagraxofusp (blastic plasmacytoid dendritic cell neoplasm, first-line)]
2021	National Institute for Health and Care Excellence (NICE)	Avelumab for untreated metastatic Merkel cell carcinoma. NICE technology appraisal guidance 691
2021	National Institute for Health and Care Excellence (NICE)	Genicular artery embolisation for pain from knee osteoarthritis. NICE interventional procedures guidance 708